BAMS
LGND icon

Bellevue Asset Management (Switzerland)’s Ligand Pharmaceuticals LGND Stock Holding History

Bellevue Asset Management (Switzerland)’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		$8.85M Sell
130,869
-22,586
-15% -$1.39M 1.35% 21
2015
Q3 		$8.2M Buy
153,455
+31,322
+26% +$1.9M 1.34% 21
2015
Q2 		$7.69M Sell
122,133
-27,202
-18% -$1.48M 1.07% 28
2015
Q1 		$7.18M Buy
+149,335
New +$5.72M 1% 35

Other funds holding LGND

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s LGND Position: Q4 2015 in Review

Bellevue Asset Management (Switzerland) reduced its Ligand Pharmaceuticals (LGND) stake by 15% in Q4 2015, selling an estimated $1.39M and leaving 130,869 shares worth $8.85M. The position accounts for 1.35% of the portfolio, ranked #21.

Bellevue Asset Management (Switzerland) first reported a position in LGND in Q1 2015 and has held it in 4 quarters since. 233 funds tracked by Wall St. Rank hold LGND as of Q4 2015.

  • Bellevue Asset Management (Switzerland) held 130,869 shares of Ligand Pharmaceuticals worth $8.85M as of Q4 2015.
  • Bellevue Asset Management (Switzerland) sold 22,586 Ligand Pharmaceuticals shares in Q4 2015, an estimated $1.39M.
  • Ligand Pharmaceuticals made up 1.35% of Bellevue Asset Management (Switzerland)'s portfolio in Q4 2015, its #21 holding.
  • Bellevue Asset Management (Switzerland) first reported a position in Ligand Pharmaceuticals in Q1 2015 and has held it in 4 quarters since.
  • 233 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2015.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q4 2015, filed 12 Feb 2016.